Trial Profile
Ascending Dose Study of the Safety of AB-SA01 When Topically Applied to Intact Skin of Healthy Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 May 2019
Price :
$35
*
At a glance
- Drugs AP SA01 (Primary)
- Indications Staphylococcal infections
- Focus Adverse reactions
- Sponsors AmpliPhi Biosciences Corporation
- 05 Dec 2016 Results published in an AmpliPhi Biosciences Corporation media release.
- 13 Sep 2016 AmpliPhi expects to report final results of the trial by the end of 2016, according to a company media release.
- 13 Sep 2016 Topline results published in the Media Release